{"id":"reiferon-retard-in-arm-1","safety":{"commonSideEffects":[{"rate":"50-90","effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":"30-70","effect":"Headache"},{"rate":"10-50","effect":"Neutropenia"},{"rate":"5-30","effect":"Thrombocytopenia"},{"rate":"10-40","effect":"Depression/mood changes"},{"rate":"5-20","effect":"Thyroid dysfunction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Interferon alfa-2a binds to type I interferon receptors on cell surfaces, triggering JAK-STAT signaling pathways that upregulate antiviral and antiproliferative genes. The retard (sustained-release) formulation extends the half-life, allowing less frequent dosing while maintaining therapeutic interferon levels. This mechanism makes it effective against chronic viral infections and certain malignancies.","oneSentence":"Reiferon Retard is a long-acting interferon alfa-2a that activates innate and adaptive immune responses to inhibit viral replication and tumor cell growth.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:04:36.959Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C"},{"name":"Chronic hepatitis B"},{"name":"Certain hematologic malignancies (e.g., chronic myeloid leukemia, lymphomas)"}]},"trialDetails":[{"nctId":"NCT01896609","phase":"PHASE4","title":"Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian Population","status":"UNKNOWN","sponsor":"MinaPharm Pharmaceuticals","startDate":"2013-06","conditions":"Chronic Hepatitis c","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pegylated interferon alfa-2a (Reiferon Retard 160 µg ®)"],"phase":"marketed","status":"active","brandName":"Reiferon Retard in Arm 1","genericName":"Reiferon Retard in Arm 1","companyName":"MinaPharm Pharmaceuticals","companyId":"minapharm-pharmaceuticals","modality":"Biologic","firstApprovalDate":"","aiSummary":"Reiferon Retard is a long-acting interferon alfa-2a that activates innate and adaptive immune responses to inhibit viral replication and tumor cell growth. Used for Chronic hepatitis C, Chronic hepatitis B, Certain hematologic malignancies (e.g., chronic myeloid leukemia, lymphomas).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}